Skip to content
Assyro AI
FDA Purple Book product · 351(a) biologic

Rebif

interferon beta-1a

Rebif, BLA 103780, is listed in the FDA Purple Book as a 351(a) biologic. This page consolidates 6 exact FDA presentation rows, and no exact reference-product relationship is asserted. It separates the BLA applicant from any unverified manufacturer and does not infer clinical labeling, pharmacy substitution, commercial availability, or patent conclusions.

351(a)BLA 103780 6 presentationsRxLicensed EMD Serono, Inc.
Approved
Mar 07, 2002
License type
351(a)
Marketing
Rx
Listed patents
0
Rebif (interferon beta-1a) is EMD Serono, Inc.'s FDA-licensed 351(a) biologic under BLA 103780, approved in 2002. No 351(k) product in the loaded Purple Book family data explicitly references Rebif; that bounded result is not a claim about future reference-product eligibility.

Sourced from the FDA Purple Book · verified Jul 02, 2026

What this Purple Book record establishes

Regulatory interpretation

BLA number

103780

Regulatory role

351(a) biologic

Applicant

EMD Serono, Inc.

Applicant is not automatically the physical manufacturer.

Presentations

6

Exact FDA presentation rows under this BLA.

Approval

Mar 07, 2002

Reference product

Not stated

Rebif is an FDA-licensed 351(a) biologic.

No 351(k) product in the loaded Purple Book family data explicitly references Rebif.

Substitution boundary

The absence of a linked 351(k) record is a bounded database result, not proof that the product can never serve as a reference product.

Key dates

Licensure & exclusivity

  1. Approval

    Approval date of this BLA submission.

    Mar 07, 2002

    24 yr 9 mo ago

  2. Today

Strengths & presentations

6 FDA presentation rows · BLA 103780

Strength

22MCG/0.5ML

Dosage form

Injection

Route

Subcutaneous

Presentation

Pre-Filled Syringe

Center

CDER

License number

1773

Product number

001

Submission type

Original

Supplement number

Not listed

Change type

Not listed

Exact presentation matrix

One row per FDA presentation under this exact BLA. Missing cells remain unavailable rather than being borrowed from another product.

Exact FDA Purple Book presentation rows for this BLA
ProductStrengthDosage formRoutePresentationLicensureMarketing
00122MCG/0.5MLInjectionSubcutaneousPre-Filled SyringeLicensedRx
00244MCG/0.5MLInjectionSubcutaneousPre-Filled SyringeLicensedRx
0038.8MCG/0.2MLInjectionSubcutaneousPre-Filled SyringeLicensedRx
0048.8MCG/0.2MLInjectionSubcutaneousAutoinjectorLicensedRx
00522MCG/0.5MLInjectionSubcutaneousAutoinjectorLicensedRx
00644MCG/0.5MLInjectionSubcutaneousAutoinjectorLicensedRx

Exact-source evidence coverage

Labeling & approval review

Current product label

Candidate awaiting exact-BLA match

FDA exposes a label link on this Purple Book row, but labeling content remains unavailable until the document is independently matched to this exact BLA and its presentations.

Inspect FDA label candidate

FDA approval evidence

Not applicable to 351(a)

A biosimilar totality-of-evidence summary is not applicable to this 351(a) record. Product-specific clinical content still requires an exact-BLA label or review source.

Human review pending

Automated BLA-level interpretation has not been marked human-reviewed. The research queue contains 1 exact-source task. Labeling and approval-review claims stay unavailable until their own match gate passes.

Reference product family

Biosimilars & interchangeables
View full family

The current record does not expose a reference-product name or an exact linked 351(k) family for Rebif.

No reference product is stated in this exact Purple Book row. This is a bounded snapshot result, not proof of real-world absence.

Published patents

BPCIA patent list

No patent-list records were published for this product. The Purple Book patent list reflects the statutory patent exchange under the BPCIA and is not exhaustive.

Practical characteristics and limits

Source-bounded interpretation

Presentation coverage

6 exact FDA presentation rows are consolidated under this BLA rather than split across duplicate pages.

Administration fields

The loaded rows list Subcutaneous and Injection; these are regulatory presentation fields, not dosing instructions.

Applicant boundary

EMD Serono, Inc. is the listed BLA applicant. The page does not relabel the applicant as manufacturer, labeler, distributor, or commercial supplier without an exact product-specific source.

Regulatory comparison

Rebif is an FDA-licensed 351(a) biologic. Family comparisons preserve each BLA's own designation and do not use Orange Book therapeutic-equivalence terminology.

Source provenance

FDA Purple Book data
Source kind · Advanced Search
Checked Jul 02, 2026
FDA source FDA source
  • advanced-searchAdvanced Search · Jul 02, 2026
  • monthly-downloadMonthly download · Jul 02, 2026

What this record does not establish

  • Purple Book marketing status is a regulatory field, not real-time commercial inventory or launch status.
  • The listed applicant or BLA holder is not automatically the product’s physical manufacturer, labeler, or distributor.
  • Biosimilar status and interchangeability are distinct FDA designations; neither is a therapeutic-equivalence code from the Orange Book.
  • A missing patent or exclusivity row is not proof that no relevant rights exist, and listed patent information is not a freedom-to-operate opinion.
  • Approved uses, dosing, warnings, and clinical evidence require the exact current product label or approval package and are not inferred from the reference product.

Change history

Record versions
  • v4Jul 02, 2026
  • v3Jul 02, 2026
  • v2Jul 02, 2026

Rebif: frequently asked questions

Licensure, biosimilar status, exclusivity, and patents for this biologic, from the FDA Purple Book.

Built directly from the FDA Purple Book database of licensed biological products. License types, approval and exclusivity dates, and the patent list match the official FDA record. The Purple Book patent list reflects the statutory BPCIA patent exchange and is not exhaustive.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo